The effect of intravenous magnesium sulfate in the treatment of patients with chronic obstructive pulmonary disease
Phase 3
- Conditions
- Chronic Obstructive Pulmonary Disease.Chronic obstructive pulmonary disease with acute exacerbation, unspecifiedJ44.1
- Registration Number
- IRCT2014111519962N1
- Lead Sponsor
- Vice Chanceller for research of Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
patient older than 18 years
acute exacerbation of COPD
Exclusion Criteria
any other underlying causes for dyspnea including heart failure, asthma, renal failure, pneumothorax, pneumoni
Not willingness to participate
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Subjective improvement of dyspnea. Timepoint: First time after the initial dose of nebulized bronchodilator and second time after the treatment protocol (3 doses of bronchodilators and even Magnesium or placebo infusion). Method of measurement: patient were asked about severity of dyspnea based on the 10 point likert scale.;Peak Expiratory Flow Rate(PEFR) improvement. Timepoint: First time after the initial dose of nebulized bronchodilator and second time after the treatment protocol (3 doses of bronchodilators and even Magnesium or placebo infusion). Method of measurement: Peak-flow-metry.
- Secondary Outcome Measures
Name Time Method Intubation during the course of admition. Timepoint: any time during first 12 hours of admition. Method of measurement: Based on patients records.;Length of hospital stay. Timepoint: time of discharge from hospital. Method of measurement: Based on patients records.